Daniel Malowany, Author at Voltron Therapeutics

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial

Daniel Malowany2023-08-25T14:20:35-04:00

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces [...]

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology TrialDaniel Malowany2023-08-25T14:20:35-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium

Daniel Malowany2023-04-05T19:21:55-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research SymposiumDaniel Malowany2023-04-05T19:21:55-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study

Daniel Malowany2023-04-05T20:03:51-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge StudyDaniel Malowany2023-04-05T20:03:51-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor

Daniel Malowany2023-04-05T18:58:29-04:00

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]

Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific AdvisorDaniel Malowany2023-04-05T18:58:29-04:00

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology

Daniel Malowany2023-04-05T13:22:39-04:00

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces [...]

Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-OncologyDaniel Malowany2023-04-05T13:22:39-04:00

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company, Announces Industry Veteran Dr. Simon Pedder has Joined the Board of Directors

Daniel Malowany2023-04-05T18:47:16-04:00

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio [...]

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company, Announces Industry Veteran Dr. Simon Pedder has Joined the Board of DirectorsDaniel Malowany2023-04-05T18:47:16-04:00

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company Announces Selection of Therapeutic Targets for Immuno-Oncology Program

Daniel Malowany2023-04-05T13:57:16-04:00

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio [...]

Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company Announces Selection of Therapeutic Targets for Immuno-Oncology ProgramDaniel Malowany2023-04-05T13:57:16-04:00

Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. Poznansky has Guest Essay Published in the New York Times

Daniel Malowany2023-04-05T12:09:16-04:00

Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. [...]

Voltron Therapeutics, Inc.’s Scientific Co-Founder Dr. Mark C. Poznansky has Guest Essay Published in the New York TimesDaniel Malowany2023-04-05T12:09:16-04:00

Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

Daniel Malowany2021-03-30T21:55:49-04:00

Voltron Therapeutics, Inc. Announces Positive Data from Animal [...]

Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19Daniel Malowany2021-03-30T21:55:49-04:00

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.

Daniel Malowany2021-03-03T16:58:40-05:00

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. [...]

Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman.Daniel Malowany2021-03-03T16:58:40-05:00

About Daniel Malowany